IP Verse

Pfizer, Inc. vs Genentech, Inc. et al.

The detailed information for PTAB case with proceeding number IPR2017-02126 filed by Pfizer, Inc. against Genentech, Inc. et al. on Oct 6, 2017. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2017-02126
Filing Date: Oct 6, 2017
Petitioner: Pfizer, Inc.
Respondent: Genentech, Inc. et al.
Status: Institution Denied
Respondent Application Number: 09436347
Respondent Tech Center: 1600
Respondent Patent Number: 7682612
Institution Decision Date: Apr 30, 2018

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
Notice of Refund	Jun 21, 2018	PAPER	BOARD
Motion for Refund of Post-Institution Fee	May 31, 2018	PAPER	PETITIONER
Trial Instituted Document	Apr 30, 2018	PAPER	BOARD
Ex 2002 Definition of Leukemia	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2003 Almasri-Reduction Expression of CD20 Antigen	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2004 Cheson-Revised Guidelines for Chronic Lymphocytic Leukemia	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2005 Kipps-Chronic lymphocytic leukemia and related diseases	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2006 Amendment & Reply	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2007 Request for Continued Examination	Feb 6, 2018	EXHIBIT	PATENT OWNER
Patent Owner Preliminary Response	Feb 6, 2018	PAPER	PATENT OWNER
Ex 2001 Chronic Lymphocytic Leukemia	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2008 09/436,347 File History-Part 2	Feb 6, 2018	EXHIBIT	PATENT OWNER
Patent Owner's Exhibit List	Feb 6, 2018	PAPER	PATENT OWNER
Ex 2008 09/436,347 File History-Part 1	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2009 Corrected Substitute Specification for App. No. 09/436,347	Feb 6, 2018	EXHIBIT	PATENT OWNER
Ex 2010 Clinical Development Success Rates 2006-2015	Feb 6, 2018	EXHIBIT	PATENT OWNER
Petitioner's Updated Mandatory Notice	Jan 31, 2018	PAPER	PETITIONER
Patent Owners' Updated Mandatory Notice	Dec 27, 2017	PAPER	PATENT OWNER
Notice of Accord Filing Date	Nov 6, 2017	PAPER	BOARD
Power of Attorney	Oct 30, 2017	PAPER	PATENT OWNER
Mandatory Notice	Oct 30, 2017	PAPER	PATENT OWNER
Ex. 1001 - White et al., U.S. Patent No. 7,682,612	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1003 - D.G. Maloney et al., "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," Blood, 84(8):2457-2466 (1994)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1004 - Maloney et al., "IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," Blood, 90(6):2188-2195 (1997)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1005 - Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," J. Clinical Oncology, 15(10):3266-3274 (1997)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1007 - O'Brien et al., "Fludarabine (FAMP) and Cyclophosphamide (CTX) Therapy in Chronic Lymphocytic Leukemia (CLL)," Blood, 88(10 Supp. 1):480a (1996)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1009 - Jensen et al., "Rapid Tumor Lysis in a Patient with B-cell Chronic Lymphocytic Leukemia and Lymphocytosis Treated with an Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)," Ann. Hematology, 77:89-91 (1998)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1012 - McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," J. Clinical Oncology, 16(8):2825-2833 (1998)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1011 - Czuczman et al., "IDEC-C2B8 and CHOP Chemoimmunotherapy of Low-Grade Lymphoma," Blood, 86(10 Supp. 1):55a (1995)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1014 - Excerpts from Clinical Oncology, Abeloff et al., Eds. (1995)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1015 - Coiffier et al., "Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A multicenter Phase II Study," Blood, 92(6):1927-1932 (1998)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1016 - Grossbard et al., "Monoclonal Antibody-Based Therapies of Leukemia and Lymphoma," Blood, 80(4):863-878 (1992)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1017 - Caroline McNeil, "Non-Hodgkin's Lymphoma Trials In Elderly Look Beyond CHOP," J. Nat'l Cancer Inst., 90(4):266-267 (Feb. 18, 1998)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1018 - U.S. Application No. 09/436,347 (dated Nov. 9, 1999)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1019 - U.S. Application No. 09/436,347, Non-Final Office Action (dated Feb. 29, 2000)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1021 - U.S. Application No. 09/436,347, Request for Continued Examination (dated Aug. 7, 2006)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1023 - Second Declaration of David P. Schenkein, M.D. (May 5, 2009)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1024 - U.S. Application No. 09/436,437, Amendment and Response to Rejection (dated May 29, 2009)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1008 - Thomas J. Kipps, "Chronic Lymphocytic Leukemia and Related Diseases," in Williams Hematology 5th Ed. (Beutler et al., eds.) 1017-1039 (1995)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1010 - I. W. Flinn et al., "Fludarabine and Cyclophosphamide as First Therapy for Indolent Lymphoproliferative Disorders: Response Rates and Toxicity," Blood, 88(10):589a (1996)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1013 - Rituxan (rituximab) labeling (Nov. 1997)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1020 - U.S. Application No. 09/436,347, Amendment and Response to Rejection (dated Aug. 29, 2000)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1022 - U.S. Application No. 09/436,437, Final Office Action (dated Feb. 19, 2009)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1030 - Pfizer, Inc. v. Biogen, Inc., Patent Owner Preliminary Response, IPR2017-01166, Paper 7 (Aug. 15, 2017)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1033 - First Declaration of David P. Schenkein, M.D. (April 14, 2008)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1025 - U.S. Application No. 09/436,437, Supplemental Amendment and Remarks (dated Aug. 24, 2009)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1026 - U.S. Application No. 09/436,437, Notice of Allowance (dated Sept., 9, 2009)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1028 - Celltrion, Inc. v. Biogen, Inc., Petition for Inter Partes Review, IPR2017-01230, Paper 2 (Mar. 31, 2017)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1029 - Celltrion, Inc. v. Biogen, Inc., Patent Owner Preliminary Response, IPR2017-01230, Paper 8 (July 18, 2017)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 1	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 2	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1031 - Declaration of Scott Bennett, Ph.D. - Part 3	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1032 - Demidem et al., "Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic Drugs," Cancer Biotherapy & Radiopharmaceuticals, 12(3):177-186 (1997)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1006 - Press Release, Genentech, Inc. "Genentech and IDEC Pharmaceuticals to Collaborate on Anti-CD20 Monoclonal Antibody for B-Cell Lymphomas," (March 16, 1995)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1034 - "Rituximab: Full Prescribing Information," (Wayback Machine)	Oct 6, 2017	EXHIBIT	PETITIONER
Ex. 1002 - Declaration of Howard Ozer, M.D., Ph.D.	Oct 6, 2017	EXHIBIT	PETITIONER
PETITION FOR INTER PARTES REVIEW '612	Oct 6, 2017	PAPER	PETITIONER
Petitioner's Power of Attorney	Oct 6, 2017	PAPER	PETITIONER